Strategic Medicine, BV (The Hague, The Netherlands) and Strategic Medicine, Inc. (PA, USA) deliver products and services to therapeutic and diagnostic companies, healthcare providers and payers and the investment community based on unique methodologies for modeling disease processes, from predisease through diagnosis, disease and patient stratification and outcome. Strategic Medicine, Inc. focuses on the development of disease models that design and incorporate a personalized health record to model the progression of a patient from genetic risk, through interaction with lifestyle and environment, to early disease detection, disease and patient stratification and treatment decision support for enhanced outcomes. This model involves the integration of disparate data and databases, evaluation of data quality and completeness, data simulation (when necessary), systems modeling and quantitative risk/opportunity evaluation. Strategic Medicine, Inc. has been involved in applying these approaches in oncology, cardiology, women's health and pediatric conditions and rare diseases, and has focused on the development of both disease- and data-agnostic infrastructures and analytics.